

## POSTER PRESENTATION

## Open Access

# Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma

Bai Liu, Lin Kong, Warren D Marcus, Xiaoyue Chen, Kaiping Han, Peter R Rhode\*, Hing C Wong

From Society for Immunotherapy of Cancer 29th Annual Meeting  
National Harbor, MD, USA. 6-9 November 2014

IL-15 exhibits potent antitumor efficacy in mouse models through its ability to promote proliferation and activation of NK cells and memory CD8<sup>+</sup> T cells. Recently, targeting approaches have been developed to direct these activities against tumor cells and minimize potential toxicities related to systemic immune activation. IL-15 and its receptor  $\alpha$  (IL-15R $\alpha$ ) are co-expressed in antigen presenting cells allowing trans-presentation of IL-15 to immune effector cells. We previously reported that the high-affinity interactions between an IL-15 superagonist (IL-15N72D) and the extracellular IL-15R $\alpha$  sushi domain (IL-15R $\alpha$ Su) could be exploited to create a functional scaffold for the design of multivalent disease-targeted protein complexes. Extending these findings to relevant tumor antigens, a tetravalent complex (2B8T2M) was generated comprising the single-chain anti-human CD20 Fv domain of Rituximab linked to the N-termini of the IL-15N72D and IL-15R $\alpha$ Su-Fc fusion proteins. As designed, this complex was found to retained IL-15 activity to induce proliferative and effector responses of CD8<sup>+</sup> T cells and NK cells as well as CD20- and Fc receptor-binding activity necessary to mediate ADCC and CDC against CD20-positive B cell lymphoma. Surprisingly, 2B8T2M ( $\geq 1$  nM) was also capable of inducing significant apoptosis of B cell lymphoma cells, which was not observed following incubation with Rituximab (Daudi cell death: 2B8T2M;  $36.5 \pm 0.5\%$  vs. Rituximab;  $8.5 \pm 0.3\%$ ). Moreover, treatment of tumor-bearing SCID mice with 2B8T2M (12.5 mg/kg, day 15, 18 post-tumor injection) was more effective than Rituximab (10 mg/kg equivalent to 12.5 mg/kg 2B8T2M) in reducing levels of CD20-positive Daudi lymphoma cells in the bone marrow (% BM Daudi cells at

day 22: 2B8T2M,  $1.4 \pm 1.3\%$  vs. Rituximab,  $28.1 \pm 6.2\%$ ; vs. PBS,  $42.1 \pm 8.0\%$ ; both  $p < 0.01$ ). This antitumor activity was dependent on each of the three binding domains of 2B8T2M. In addition, 5 mg/kg 2B8T2M treatment of Daudi tumor-bearing SCID mice significantly prolonged survival compared to PBS control- and 10 mg/kg Rituximab-treatment groups (median survival: 2B8T2M, 42 days vs. Rituximab, 35 days; vs. PBS, 27 days; both  $p < 0.01$ ). In cynomolgus monkeys, 2B8T2M administration (5 mg/kg, day 0, 3) also exhibited greater activity than Rituximab (10 mg/kg) for depleting B cells in the blood and lymph nodes ( $p < 0.05$ ). 2B8T2M treatment was well tolerated in each of these models. Together, these findings demonstrate that tumor antigen-targeted IL-15 complexes can stimulate and direct immune responses to more effectively eliminate tumor cells than related therapeutic antibodies. Thus, these molecules represent novel and promising targeted immunotherapeutics for treating cancer.

## Acknowledgements

NIH/NCI grant CA174091 (Wong).

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P122

**Cite this article as:** Liu et al.: Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P122.